Vorinostat is a drug that has been approved by the U.S. Food and Drug Administration (FDA) under the brand name Zolinza for the treatment of a certain type of cancer.Vorinostat is also being studied as an investigational drug as part of a strategy to cure HIV infection.As an investigational HIV drug, vorinostat belongs to a group of drugs called latency-reversing agents.